Experimental immune cells show promise for COVID lung crisis
NCT ID NCT04582201
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 18 times
Summary
This early-phase study tested a new cell therapy called agenT-797 in 20 adults hospitalized with moderate to severe COVID-19-related lung failure (ARDS). The main goal was to check safety and find the right dose. Researchers also looked at how long patients needed breathing machines, death rates, and changes in inflammation and virus levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY DISTRESS SYNDROME, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky, 40207, United States
-
Saint John's Cancer Institute
Santa Monica, California, 90404, United States
-
Weill Cornell Medicine New York Presbyterian
New York, New York, 10022, United States
Conditions
Explore the condition pages connected to this study.